Rainer Johannes Klement1. 1. Department of Radiotherapy and Radiation Oncology, Leopoldina Hospital Schweinfurt, Schweinfurt, Germany.
Abstract
PURPOSE OF REVIEW: Altered glucose metabolism in cancer cells is an almost ubiquitous observation, yet hardly exploited therapeutically. However, ketogenic diets have gained growing attention in recent years as a nontoxic broad-spectrum approach to target this major metabolic difference between normal and cancer cells. Although much research still needs to be done, new knowledge has been gained about the optimal utilization of ketogenic diets for cancer treatment that this review aims to summarize. RECENT FINDINGS: Although most preclinical studies indicate a therapeutic potential for ketogenic diets in cancer treatment, it is now becoming clear that not all tumors might respond positively. Early clinical trials have investigated ketogenic diets as a monotherapy and - while showing the safety of the approach even in advanced cancer patients - largely failed to prove survival prolonging effects. However, it gradually became clear that the greatest potential for ketogenic diets is as adjuvant treatments combined with pro-oxidative or targeted therapies initiated in early stages of the disease. Beneficial effects on body composition and quality of life have also been found. SUMMARY: Ketogenic diets against cancer are worth further exploration, both in the laboratory and clinically. Patients wishing to undertake a ketogenic diet during therapy should receive dietary counselling to avoid common mistakes and optimize compliance. Future research should focus more on important clinical endpoints.
PURPOSE OF REVIEW: Altered glucose metabolism in cancer cells is an almost ubiquitous observation, yet hardly exploited therapeutically. However, ketogenic diets have gained growing attention in recent years as a nontoxic broad-spectrum approach to target this major metabolic difference between normal and cancer cells. Although much research still needs to be done, new knowledge has been gained about the optimal utilization of ketogenic diets for cancer treatment that this review aims to summarize. RECENT FINDINGS: Although most preclinical studies indicate a therapeutic potential for ketogenic diets in cancer treatment, it is now becoming clear that not all tumors might respond positively. Early clinical trials have investigated ketogenic diets as a monotherapy and - while showing the safety of the approach even in advanced cancerpatients - largely failed to prove survival prolonging effects. However, it gradually became clear that the greatest potential for ketogenic diets is as adjuvant treatments combined with pro-oxidative or targeted therapies initiated in early stages of the disease. Beneficial effects on body composition and quality of life have also been found. SUMMARY: Ketogenic diets against cancer are worth further exploration, both in the laboratory and clinically. Patients wishing to undertake a ketogenic diet during therapy should receive dietary counselling to avoid common mistakes and optimize compliance. Future research should focus more on important clinical endpoints.
Authors: Daniela D Weber; Sepideh Aminzadeh-Gohari; Maheshwor Thapa; Anna-Sophia Redtenbacher; Luca Catalano; Tânia Capelôa; Thibaut Vazeille; Michael Emberger; Thomas K Felder; René G Feichtinger; Peter Koelblinger; Guido Dallmann; Pierre Sonveaux; Roland Lang; Barbara Kofler Journal: Cancer Metab Date: 2022-07-18
Authors: Elisabet Cuyàs; Salvador Fernández-Arroyo; Maria Buxó; Sonia Pernas; Joan Dorca; Isabel Álvarez; Susana Martínez; Jose Manuel Pérez-Garcia; Norberto Batista-López; César A Rodríguez-Sánchez; Kepa Amillano; Severina Domínguez; Maria Luque; Idoia Morilla; Agostina Stradella; Gemma Viñas; Javier Cortés; Sara Verdura; Joan Brunet; Eugeni López-Bonet; Margarita Garcia; Samiha Saidani; Jorge Joven; Begoña Martin-Castillo; Javier A Menendez Journal: Aging (Albany NY) Date: 2019-05-09 Impact factor: 5.682
Authors: Ping-Yuan Wang; Jin Ma; Jie Li; Matthew F Starost; Michael J Wolfgang; Komudi Singh; Mehdi Pirooznia; Ju-Gyeong Kang; Paul M Hwang Journal: Cancer Prev Res (Phila) Date: 2020-09-21